Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TLSI Stock Forecast 2026-2027
$3.77
Current Price
$231.54M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TLSI Price Targets
+191.8%
To High Target of $11.00
+112.2%
To Median Target of $8.00
+85.7%
To Low Target of $7.00
TLSI Price Momentum
+18.9%
1 Week Change
+49.6%
1 Month Change
-27.4%
1 Year Change
-46.0%
Year-to-Date Change
-52.6%
From 52W High of $7.95
+71.4%
From 52W Low of $2.20
📊 TOP ANALYST CALLS
Did TLSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Trisalus is one of their latest high-conviction picks.
Latest TLSI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, TLSI has a bullish consensus with a median price target of $8.00 (ranging from $7.00 to $11.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $3.77, the median forecast implies a 112.2% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TLSI Analyst Ratings
5
Buy
0
Hold
0
Sell
TLSI Price Target Range
Low
$7.00
Average
$8.00
High
$11.00
Current: $3.77
Latest TLSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TLSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | Lake Street | Frank Takkinen | Buy | Maintains | $8.00 |
| Mar 9, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 6, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 17, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 28, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 13, 2025 | Lake Street | Buy | Initiates | $N/A | |
| Jan 24, 2025 | Roth MKM | Buy | Reiterates | $N/A | |
| Dec 17, 2024 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 15, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 11, 2024 | Roth MKM | Buy | Initiates | $N/A | |
| Oct 25, 2024 | Northland Capital Markets | Outperform | Initiates | $N/A | |
| Sep 16, 2024 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jun 27, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 30, 2024 | Canaccord Genuity | Buy | Initiates | $N/A | |
| May 10, 2024 | JonesTrading | Buy | Initiates | $N/A |
TriSalus Life Sciences Inc. (TLSI) Competitors
The following stocks are similar to Trisalus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TriSalus Life Sciences Inc. (TLSI) Financial Data
TriSalus Life Sciences Inc. has a market capitalization of $231.54M with a P/E ratio of 0.1x. The company generates $44.88M in trailing twelve-month revenue with a -60.9% profit margin.
Revenue growth is -2.9% quarter-over-quarter, while maintaining an operating margin of -94.5% and return on equity of +205.8%.
Valuation Metrics
Market Cap
$231.54M
Enterprise Value
$201.49M
P/E Ratio
0.1x
PEG Ratio
0.0x
Price/Sales
5.0x
Growth & Margins
Revenue Growth (YoY)
-2.9%
Gross Margin
+86.2%
Operating Margin
-94.5%
Net Margin
-60.9%
EPS Growth
-2.9%
Financial Health
Cash/Price Ratio
+24.4%
Current Ratio
5.8x
Debt/Equity
269.3x
ROE
+205.8%
ROA
-35.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
TriSalus Life Sciences Inc. (TLSI) Business Model
About TriSalus Life Sciences Inc.
What They Do
Develops innovative cancer therapies using unique technologies.
Business Model
TriSalus Life Sciences operates as a biopharmaceutical company that focuses on developing therapies for cancer treatment, specifically targeting solid tumors. The company generates revenue by advancing its proprietary technologies, such as Pressure-Enabled Drug Delivery (PEDD), through clinical trials and partnerships with research institutions and healthcare providers to bring these treatments to market.
Additional Information
The company's emphasis on addressing vascular perfusion and immune suppression in tumor environments highlights its commitment to improving patient outcomes in challenging cancer treatments. TriSalus Life Sciences is positioned within the biotechnology industry, which offers substantial growth potential as it aims to transform oncological therapeutic strategies.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
102
CEO
Ms. Mary T. Szela B.S.N., M.B.A.
Country
United States
IPO Year
2021
Website
trisaluslifesci.comTriSalus Life Sciences Inc. (TLSI) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for investors of TriSalus Life Sciences Inc. (NASDAQ: TLSI). Interested parties should contact Danielle Peyton for details.
Why It Matters
Investigations into TriSalus Life Sciences may indicate potential legal issues or financial instability, prompting heightened scrutiny and risk assessment for current and prospective investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Schall Law Firm is investigating TriSalus Life Sciences (NASDAQ: TLSI) for potential securities law violations, including issuing misleading statements to investors.
Why It Matters
TriSalus Life Sciences faces scrutiny for potential securities law violations, which could lead to legal liabilities, affect stock price, and erode investor trust.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
TriSalus Life Sciences (Nasdaq: TLSI) will host a virtual KOL event on June 24, 2026, at 8:00 AM ET to discuss findings from a new real-world outcomes study on their cancer therapies.
Why It Matters
TriSalus's KOL event showcases promising real-world study results, potentially enhancing investor confidence and interest in the company's innovative cancer treatment approach.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Holzer & Holzer is investigating TriSalus Life Sciences (NASDAQ: TLSI) for potential federal securities law violations after the company reported decreased Q1 2026 revenue and lowered full-year guidance, causing a stock price drop.
Why It Matters
TriSalus Life Sciences faces scrutiny over potential securities law violations, following disappointing financial results and lowered guidance, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating TriSalus Life Sciences (NASDAQ: TLSI) for potential federal securities law violations. TLSI reported Q1 2026 revenue of $8.9 million.
Why It Matters
The investigation into TriSalus Life Sciences for potential securities law violations could indicate financial instability or legal risks, impacting investor confidence and stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
TriSalus Life Sciences Inc. has revised its revenue guidance for 2026 from $60-$62 million to $54-$57 million following a Q1 earnings miss.
Why It Matters
TriSalus's lowered revenue guidance signals potential financial instability, raising concerns about its growth prospects and impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TLSI Stock
What is TriSalus Life Sciences Inc.'s (TLSI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, TriSalus Life Sciences Inc. (TLSI) has a median price target of $8.00. The highest price target is $11.00 and the lowest is $7.00.
Is TLSI stock a good investment in 2026?
According to current analyst ratings, TLSI has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TLSI stock?
Wall Street analysts predict TLSI stock could reach $8.00 in the next 12 months. This represents a 112.2% increase from the current price of $3.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is TriSalus Life Sciences Inc.'s business model?
TriSalus Life Sciences operates as a biopharmaceutical company that focuses on developing therapies for cancer treatment, specifically targeting solid tumors. The company generates revenue by advancing its proprietary technologies, such as Pressure-Enabled Drug Delivery (PEDD), through clinical trials and partnerships with research institutions and healthcare providers to bring these treatments to market.
What is the highest forecasted price for TLSI TriSalus Life Sciences Inc.?
The highest price target for TLSI is $11.00 from at , which represents a 191.8% increase from the current price of $3.77.
What is the lowest forecasted price for TLSI TriSalus Life Sciences Inc.?
The lowest price target for TLSI is $7.00 from at , which represents a 85.7% increase from the current price of $3.77.
What is the overall TLSI consensus from analysts for TriSalus Life Sciences Inc.?
The overall analyst consensus for TLSI is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are TLSI stock price projections?
Stock price projections, including those for TriSalus Life Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 3:24 AM UTC